Safety and Efficacy of IDegLira Titrated Once Weekly vs Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

March 3, 2017. This open-label trial evaluated the impact of IDegLira (combined insulin degludec and the glucagon-like peptide-1 inhibitor liraglutide) once or twice weekly in insulin-naïve adults with type 2 diabetes inadequately controlled on metformin ± pioglitazone. A total of 420 patients were randomized to this 32-week non-inferiority trial. IDegLira was titrated either once or twice weekly based on mean pre-breakfast plasma glucose readings. With once-weekly titration, mean A1C decreased from 8.2% to 6.1%; reductions for twice-weekly titration were from 8.1% to 6.0%. In addition, approximately 90% of patients in each arm achieved A1C levels <7.0%, weight change was −1.0 kg vs −2.0 kg for once- vs twice-weekly titration, and confirmed symptomatic hypoglycemia was low in both arms. Both study arms experienced similar adverse event rates, and mean IDegLira dose at 32 weeks was 41 dose steps (41 U IDeg/1.48 mg Lira) for both arms. Click here for full article